Online ISSN: 2788-6867

Keywords : Breast cancer

Computational Analysis of Interleukin 17A Activity in Breast Cancer Patients Using Bioinformatics Methods

Abdalrahman S. Mohammed‬; Abbas A. Al-Janabi

Journal of Applied Sciences and Nanotechnology, 2022, Volume 2, Issue 2, Pages 79-85
DOI: 10.53293/jasn.2021.3878.1052

In the current study, bioinformatics approach has been utilized to discover the sequences and structures analysis of IL-17A of breast cancer and compares with normal sequence from NCBI. The current study was aimed to discuss the possibility of using IL-17A as a marker for patients with breast cancer. Also, the effect of mutation on the physicochemical properties and structure of IL-17A. Sixty blood samples were examined from patients with breast cancer (aged between 20 and 75 years old). In patients with breast cancer, there were missense mutations and deletion mutations detected by BLAST. Furthermore, the current study determined the physicochemical properties of IL-17A, such as their hydrophilic nature; alpha–helical structure, and 3D structure. The results of this study show that IL-17A consider as a marker for the patient with breast cancer. Also, the mutations on IL-17A gene affected the structure and physicochemical properties of the Interleukin-17A protein complex.

Determination of Interferon Gamma Protein in Serum of Breast Cancer Patients Using the ELISA

Noor E. Hassan; Abbas A. Mohammed

Journal of Applied Sciences and Nanotechnology, 2022, Volume 2, Issue 1, Pages 37-48
DOI: 10.53293/jasn.2021.4295.1089

Interferon gamma (IFN-γ) is a cytokine involved in the induction and modulation of various immune responses. INF-γ has recently been associated with breast cancer and the stage of the disease. Also, it can be used as a cancer marker in determining disease activity. The ELISA test is a technique for identifying antigens in biological materials. The ELISA test is used for the detection of antibodies against target antigen through highly antibody-antigen interactions. In this study, the blood samples were taken from 88 Iraqis, 30 healthy controls, and 58 breast cancer patients (ranging from 35 to 52 years of age). During a visit to the AL Amal National Hospital for Cancer Treatment in Baghdad, Iraq, these patient samples were taken October 2020 - January 2021. Depending on the color changes to yellow, the results of this study were determined under wavelength of 450 nm to reveal the optical density (OD) via spectrophotometrically. The OD value is proportional to the amount of human IFN-γ in the sample of the healthy control and the cancer patients. The blood concentration of IFN-γ was substantially greater in women with breast cancer than in the control group (43.15 ± 4.68 pg/ml vs. 18.8 ± 3.89 pg/ml), respectively. Our results showed an elevation of Interferon-gamma (IFN-γ) in most of the serum samples from women with breast cancer. The conclusions of this study are the main findings, INF-y protein was employed as a marker and assistance in diagnosing breast cancer based on the results of the calculation of protein concentration from the ELISA test.